Shionogi presents positive Ph II/III results for COVID-19 antiviral S-217622

31 January 2022

Japanese drug major Shionogi (TYO: 4507) edged up 2.4% to 6,464 yen this morning, as it presented the results up to day six of the Phase IIa part of a Phase II/III clinical trial of S-217622, an orally administered antiviral drug for COVID-19.

US pharma giant Pfizer (NYSE: PFE) is already marketing a COVID-19 pill called Paxlovid (nirmatrelvir/ritonavir) that has a similar mechanism to Shionogi's S-217622.

This study is a randomized, placebo-controlled, double-blind study in Japanese adults, in which the antiviral effects and safety of this drug given orally once daily for five days were evaluated. The information presented is outlined below.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK